Anders Pedersen
Chief Operating Officer bij GALECTO, INC.
Vermogen: 2 922 $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Anders Pedersen
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 19 | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.
14
| Subsidiary | Pharmaceuticals: Major | 14 |
The University of New Mexico
10
| College/University | Other Consumer Services | 10 |
AGC Biologics A/S
 AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark.
7
| Subsidiary | Pharmaceuticals: Major | 7 |
Life Cycle Pharma A/S
1
| Private Company | 1 | |
Recepticon ApS
 Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.
1
| Extinct | Pharmaceuticals: Major | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Anders Pedersen via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| COMPUGEN LTD. | Biotechnology | President | |
OrbiMed Capital LLC
 OrbiMed Capital LLC Financial ConglomeratesFinance Part of OrbiMed Advisors LLC, OrbiMed Capital LLC is a private company based in New York, NY. | Financial Conglomerates | Private Equity Analyst | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| PCI BIOTECH HOLDING ASA | Biotechnology | Director/Board Member Director/Board Member | |
OrbiMed Israel Partners LP
 OrbiMed Israel Partners LP Investment ManagersFinance OrbiMed Israel Partners LP seeks investment opportunities in life science companies located in Israel. The fund targets companies operating in the fields of biotechnology, pharmaceutical, medical device and diagnostics. It provides financing for seed, early, later and growth stage capital requirements. | Investment Managers | Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous | Corporate Officer/Principal Chief Investment Officer | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| Copenhagen Business School | College/University | Graduate Degree Corporate Officer/Principal | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chairman Director of Finance/CFO | |
| University of Copenhagen | College/University | Graduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
| Freie Universität Berlin | College/University | Doctorate Degree Doctorate Degree | |
| University of Southern Denmark | College/University | Undergraduate Degree Doctorate Degree | |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal Director of Finance/CFO | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member General Counsel | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor Private Equity Investor | |
Verge Management LLC
 Verge Management LLC Investment ManagersFinance Verge Management LLC (Verge fund) is a venture capital firm founded in 2003. The firm is headquartered in Albuquerque, New Mexico. | Investment Managers | Founder Private Equity Investor | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Director of Investments Director of Investments | |
Otic Pharma Ltd.
 Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA. | Pharmaceuticals: Major | Chairman | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Director/Board Member Director of Finance/CFO | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Compugen, Inc. (United States) | Corporate Officer/Principal | ||
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Nucleix Ltd.
 Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Medical/Nursing Services | Director/Board Member | |
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Investment Managers | Director/Board Member | |
| LOGICBIO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ELEDON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Emendo Biotherapeutics, Inc.
 Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
| BIOMX INC. | Biotechnology | Director/Board Member | |
ADARx Pharmaceuticals, Inc.
 ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services ADARx Pharmaceuticals, Inc. operates as RNA base-editing company. The company is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Immpact Bio USA, Inc.
 Immpact Bio USA, Inc. BiotechnologyHealth Technology ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA. | Biotechnology | Director/Board Member | |
| ADICET BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Compugen Usa, Inc. | President | ||
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 18 |
| Denemarken | 17 |
| Israël | 7 |
| Zweden | 4 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 30 |
| Finance | 8 |
| Consumer Services | 8 |
| Commercial Services | 4 |
| Miscellaneous | 2 |
Operationeel
| Director/Board Member | 299 |
| Corporate Officer/Principal | 98 |
| Chairman | 58 |
| Independent Dir/Board Member | 53 |
| Chief Executive Officer | 52 |
Sterkste connecties
| Insiders | |
|---|---|
| Gunnar Magnus Modee Persson | 51 |
| Søren Lemonius | 39 |
| Chau Khuong | 38 |
| Flemming Ørnskov | 34 |
| Carl Samuel Goldfischer | 31 |
| Erez Chimovits | 30 |
| Stephan Christgau | 29 |
| Nanna Liebach Lüneborg | 29 |
| Amit Munshi | 26 |
| Chandra Paul Leo | 22 |
| Søren Møller | 21 |
| Karen Wagner | 17 |
| Delores M. Etter | 17 |
| Hans Schambye | 16 |
| William Bice | 15 |
- Beurs
- Insiders
- Anders Pedersen
- Bedrijfsconnecties
